Home › NCT07765446

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults ≥18 years with confirmed solid tumors
* Planned treatment with paclitaxel-based chemotherapy
* ECOG performance status 0-2

Exclusion Criteria:

* Pre-existing peripheral neuropathy
* Conditions or medications that may interfere with neuropathy assessment
* Prior exposure to neurotoxic chemotherapy
* Use of medications known to mitigate CIPN
* Significant medical conditions that may increase study risk

About the study

This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).

What is being tested

• SIR2501 (drug)

Sponsor: Sironax USA, Inc. · Participants: 18 · Started: Aug 21, 2026

Contact the study team

• Medical Monitor · Phone: +1-617-580-2520

Official record on ClinicalTrials.gov — NCT07765446

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.